Abstract
Ductal breast carcinoma in situ (DCIS) is regarded as a precursor to invasive breast cancer. The progression from in situ to invasive cancer is however little understood. We compared some tumour markers in invasive and in situ breast carcinomas trying to find steps in this progression. We designed a semi-experimental setting and compared histopathological grading and tumour marker expression in pure DCIS (n = 194), small invasive lesions (n = 127) and lesions with both an invasive and in situ component (n = 305). Grading was done according to the Elston-Ellis and EORTC classification systems, respectively. Immunohistochemical staining was conducted for p53, c-erbB-2, Ki-67, ER, PR, bcl-2 and angiogenesis. All markers correlated with grade rather than with invasiveness. No marker was clearly associated with the progression from in situ to invasiveness. The expression of tumour markers was almost identical in the 2 components of mixed lesions. DCIS as a group showed a more 'malignant picture' than invasive cancer according to the markers, probably, due to a higher proportion of poorly differentiated lesions. The step between in situ and invasive cancer seems to occur independently of tumour grade. The results suggest that well-differentiated DCIS progress to well-differentiated invasive cancer and poorly differentiated DCIS progress to poorly differentiated invasive cancer.
MeSH Terms
Biomarkers, Tumor/analysis
Breast Neoplasms/chemistry,pathology
Carcinoma, Ductal, Breast/chemistry,pathology
Carcinoma, Intraductal, Noninfiltrating/chemistry,pathology
Cell Differentiation
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
Ki-67 Antigen/analysis
Neoplasm Invasiveness
Neoplasm Staging
Neovascularization, Pathologic/metabolism
Proto-Oncogene Proteins c-bcl-2/analysis
Receptor, ErbB-2/analysis
Receptors, Estrogen/analysis
Receptors, Progesterone/analysis
Tumor Suppressor Protein p53/analysis
Chemicals
Biomarkers, Tumor
Ki-67 Antigen
Proto-Oncogene Proteins c-bcl-2
Receptors, Estrogen
Receptors, Progesterone
Tumor Suppressor Protein p53
Receptor, ErbB-2
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Wärnberg F
Department of Surgery, University Hospital Uppsala, S-751 85 Uppsala, Sweden.
Nordgren H
Bergkvist L
Holmberg L
References (21)
21 references, click to expand
-
The clinical significance of pre-invasive breast carcinoma.
Cancer. 1980 Aug 15;46(4 Suppl):919-25
PMID: 7397668
-
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
J Pathol. 1999 Mar;187(4):396-402
PMID: 10398097
-
New aspects of the natural history of in situ and invasive carcinoma in the female breast. Results from autopsy investigations.
Verh Dtsch Ges Pathol. 1985;69:88-95
PMID: 3006395
-
Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation.
Radiology. 1989 Jul;172(1):235-41
PMID: 2544922
-
Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome.
Am Surg. 1990 Jul;56(7):428-32
PMID: 2164336
-
Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.
Br J Cancer. 1990 Jun;61(6):869-72
PMID: 2164835
-
Breast conserving surgery in the management of in situ breast carcinoma.
Eur J Surg Oncol. 1991 Jun;17(3):258-64
PMID: 1646128
-
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
J Clin Pathol. 1992 Jan;45(1):16-20
PMID: 1346789
-
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Hum Pathol. 1992 Sep;23(9):974-9
PMID: 1355464
-
Ductal carcinoma in situ.
Cancer Invest. 1992;10(5):443-54
PMID: 1327429
-
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.
N Engl J Med. 1993 Jun 3;328(22):1581-6
PMID: 8292119
-
Microvessel density and distribution in ductal carcinoma in situ of the breast.
J Natl Cancer Inst. 1994 Apr 20;86(8):614-9
PMID: 7511693
-
Ductal carcinoma in situ: a proposal for a new classification.
Semin Diagn Pathol. 1994 Aug;11(3):167-80
PMID: 7831528
-
Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Cancer. 1995 Apr 15;75(8):2123-31
PMID: 7697603
-
Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.
Breast Cancer Res Treat. 1995 Jun;34(3):253-63
PMID: 7579490
-
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.
J Pathol. 1995 Nov;177(3):275-83
PMID: 8551390
-
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.
J Clin Oncol. 1996 Mar;14(3):754-63
PMID: 8622021
-
A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma.
Histopathology. 1996 Nov;29(5):397-409
PMID: 8951484
-
Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast.
J Pathol. 1997 Feb;181(2):207-12
PMID: 9120727
-
The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).
Cancer. 1997 Nov 1;80(9):1740-5
PMID: 9351542
-
Intraductal carcinoma of the breast: follow-up after biopsy only.
Cancer. 1982 Feb 15;49(4):751-8
PMID: 6275978